NCT02964572View on ClinicalTrials.gov

Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes

NACompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
Type2 Diabetes Mellitus
Interventions
DRUG

Glimepiride

In accordance with the standard treatment guidelines of diabetes, glimepiride as a drug of active comparator will be administered to improve blood sugar in patients with poorly controlled blood sugar.

DRUG

Empagliflozin

Empagliflozin as a drug of experimental will be administered to improve blood sugar in patients with poorly controlled blood sugar.

Trial Locations (1)

03722

Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes center, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT02964572 - Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes | Biotech Hunter | Biotech Hunter